

# CRSwNP SIGNIFICANTLY AFFECTS QUALITY OF LIFE

## Symptom burden of CRSwNP

### Severe chronic disease<sup>1</sup>



Many patients endure symptoms for years before seeking medical attention

Symptoms often persist >6 months at a time:



Loss of smell



Nasal obstruction/  
blockage



Nasal drainage

### Smell and taste loss<sup>2</sup>

Ranked as SNOT-22 symptom “most affecting their health” by **87%** of patients

### Nasal congestion<sup>3</sup>

**94%**

of patients with CRSwNP experience nasal congestion/obstruction/blockage

### Sleep disturbance<sup>4</sup>

**>75%** of patients experience reduced sleep quality

### INCS and SCS Use<sup>6,7</sup>

Daily INCS and saline rinses recommended for all patients with CRSwNP<sup>6</sup>

**23%–71%** use SCS<sup>7\*</sup>



### Impaired emotional and social well-being<sup>1</sup>

Higher SNOT-22 scores indicate increased risk for major depressive disorder<sup>5</sup>

### AEs associated with SCS use<sup>8</sup>

## Symptom and surgery recurrence<sup>9-12</sup>

**~46%**

of patients with CRSwNP undergo endoscopic sinus surgery (ESS)<sup>9</sup>

### Symptom recurrence: 6 months post-ESS

**35%** polyps recur<sup>10</sup>

**76%** smell loss recurs<sup>11†</sup>

**68%** nasal congestion/  
obstruction recurs<sup>11†</sup>

**96%**

had partially controlled or uncontrolled disease within 5 years of surgery<sup>12‡</sup>

## Treatment burden of CRSwNP

HRQoL impairments caused by CRSwNP are comparable with those of other serious chronic diseases<sup>1</sup>

\*Meta-analysis of 6 studies reporting a range of patients with CRSwNP using SCS.<sup>7</sup> †Thick nasal discharge and facial pain/pressure recurred in 66% and 53% of patients, respectively.<sup>11</sup> ‡Patients with severe CRSwNP.<sup>12</sup> AE, adverse event; CRSwNP, chronic rhinosinusitis with nasal polyps; HRQoL, health-related quality of life; INCS, intranasal corticosteroids; SCS, systemic corticosteroids; SNOT-22, 22-item Sinonasal Outcomes Test.

1. Bachert C, et al. *J Asthma Allergy*. 2021;14:127-134. 2. Mullol J, et al. *J Allergy Clin Immunol Pract*. 2022;10(4):1086-1095.e5. 3. Stevens WW, et al. *J Allergy Clin Immunol Pract*. 2019;7(8):2812-2820.e3. 4. Mullol J, et al. *J Allergy Clin Immunol Pract*. 2022;10(6):1434-1453.e9. 5. Liu DT, et al. *Laryngoscope Invest Otolaryngol*. 2022;7(1):29-35. 6. Fokkens WJ, et al. *Rhinology*. 2020;58(Suppl S29):1-464. 7. Chen S, et al. *Curr Med Res Opin*. 2020;36(11):1897-1911. 8. De Corso E, et al. *J Pers Med*. 2022;12(6):897. 9. Khan A, et al. *Rhinology*. 2019;57(5):343-351. 10. DeConde AS, et al. *Laryngoscope*. 2017;127(3):550-555. 11. DeConde AS, et al. *Int Forum Allergy Rhinol*. 2015;5(1):36-45. 12. Zhang L, et al. *Rhinology*. 2020;58(2):126-135.


# CRSwNP SIGNIFICANTLY AFFECTS QUALITY OF LIFE

## Symptom burden of CRSwNP

Severe Chronic Disease

Mild and Moderate

### Loss of sense of smell increases patients' psychological burden



HRQoL impairments caused by CRSwNP are comparable with those of other severe chronic diseases

CRSwNP, chronic rhinosinusitis with nasal polyps; SCL-90-R, Symptom Checklist-90-Revised. Chung JH, et al. *Ann Otol Rhinol Laryngol*. 2015;124(8):663-670.

# CRSwNP SIGNIFICANTLY AFFECTS QUALITY OF LIFE

## Symptom burden of CRSwNP

### Severe Chronic Disease




More patients report symptoms for years before seeking medical attention

Symptoms often persist 18 months or a longer

### Small and Underused

Reported as 2022-23 symptom "most affecting their health" by 87% of patients

## CRSwNP impairs sleep quality and nasal patency and increases daytime sleepiness<sup>1</sup>



### Sleep apnea<sup>2</sup>



of patients with CRSwNP are at increased risk of sleep apnea\*

### Sleep disturbances/impairments include<sup>3</sup>:



Snoring



Fragmented sleep

## Treatment burden of CRSwNP

HRQoL impairment caused by CRSwNP and comorbidities with those of severe asthma/chronic disease

\*The Berlin Questionnaire was used as a screening tool for the identification of patients at high risk of obstructive sleep apnea.<sup>2</sup> CRSwNP, chronic rhinosinusitis with nasal polyps.  
**1.** Bachert C, et al. *J Asthma Allergy*. 2021;14:127-134. **2.** Värendh M, et al. *Rhinology*. 2017;55(1):45-52. **3.** Mullol J, et al. *J Allergy Clin Immunol Pract*. 2022;10(6):1434-1453.e9.

# CRSwNP SIGNIFICANTLY AFFECTS QUALITY OF LIFE

## Symptom burden of CRSwNP


Severe chronic disease

Small and little help

Many patients endure symptoms for years before seeking medical attention

Rated as "not at all" or "not very" helpful by 87% of patients

## Patients with CRSwNP have impaired social well-being



## Treatment burden of CRSwNP

HRQL impairments caused by CRSwNP are comparable with those of other serious chronic diseases

CRSwNP, chronic rhinosinusitis with nasal polyps.  
Bachert C, et al. *J Asthma Allergy*. 2021;14:127-134.

# CRSwNP SIGNIFICANTLY AFFECTS QUALITY OF LIFE

## Symptom burden of CRSwNP


Severe Chronic Disease

Small and Localized

More patients report symptoms for each before seeking medical attention

Reported as "Small and Localized" symptoms "less severe than health" by 87% of patients

## Common adverse events and conditions associated with SCS use\*



Quality of life impairments caused by CRSwNP are comparable with those of other severe chronic diseases

\*From a survey of Italian otorhinolaryngologists.

CRSwNP, chronic rhinosinusitis with nasal polyps; SCS, systemic corticosteroids.

De Corso E, et al. *J Pers Med.* 2022;12(6):897.


# CRSwNP SIGNIFICANTLY AFFECTS QUALITY OF LIFE




Over 95% of patients had sign and symptom recurrence within 3 years of surgery, regardless of surgical approach

■ RESS+Draf 3   ■ RESS   ■ FESS


## Congestion



## Loss of smell



## SNOT-22



MAT-AE-2400444-V1-JULY2024

CRSwNP, chronic rhinosinusitis with nasal polyps; Draf 3, endoscopic modified Lothrop procedure; FESS, functional endoscopic sinus surgery; RESS, radical endoscopic sinus surgery; SNOT-22, 22-item Sinonasal Outcomes Test; VAS, visual analog scale. Zhang L, et al. *Rhinology*. 2020;58(2):126-135.